ライフサイエンスコーパス: matrix metalloproteinase 1

1 tissue growth factor and tissue inhibitor of matrix metalloproteinase 1.

2 , which is resistant to degradation by human matrix metalloproteinase 1.

3 cell migration through the up-regulation of matrix metalloproteinase 1.

4 n-6, monocyte chemoattractant protein 1, and matrix metalloproteinase 1.

5 that obtained via direct immunodepletion of matrix metalloproteinase-1.

6 ), cyclooxygenase-2, and tissue inhibitor of matrix metalloproteinase-1.

7 lammation-responsive genes including SAA and matrix metalloproteinase-1.

8 nd interleukin-8 and the remodeling mediator matrix metalloproteinase-1.

9 f extracellular matrix-modifying enzymes and matrix metalloproteinase-1.

10 was further characterized by upregulation of matrix metalloproteinases 1, 10, and 13, cathepsin L2, c

11 signaling pathway, and induces expression of matrix metalloproteinases 1, 2, and 3.

12 raised reactive oxygen species production or matrix metalloproteinase-1, -2 and -9 activity nor decre

13 sion across an ECM layer was quantitated and matrix metalloproteinase-1, -2, -3, -9, and -11 gene and

14 chemoattractant protein-1, cyclooxygenase-2, matrix metalloproteinases-1, -2, and -3 (MMP-1, -2, and

15 The externalized MSP domain is cleaved by Matrix metalloproteinase 1/2 (Mmp1/2).

16 The up-regulated production of matrix metalloproteinases 1, 3, and 13 and cytokines IL-

17 ecan mRNA levels and increased the levels of matrix metalloproteinases 1, 3, and 13 mRNA, as well as

18 dorferi infection revealed colocalization of matrix metalloproteinase-1, a degradative enzyme that de

19 al encoding angiogenic regulators, including matrix metalloproteinase-1, an interstitial collagenase,

20 in basic calcium phosphate crystal-mediated matrix metalloproteinase 1 and 3 expression in human fib

21 with elevated levels of tissue inhibitor of matrix metalloproteinase 1 and elastin in the infarct (P

22 se, in both groups there was upregulation of matrix metalloproteinase 1 and laminin 5 in the tumors.

23 Higher levels of tissue inhibitor of matrix metalloproteinase 1 and soluble ST2 at baseline a

24 280-320 nm) causes these changes by inducing matrix metalloproteinase 1 and suppressing type I collag

25 Certain Ets-1-associated genes, namely matrix metalloproteinase 1 and vascular endothelial grow

26 helin-1 inhibited both protein expression of matrix metalloproteinase 1 and zymographic activity excl

27 Matrix metalloproteinase-1 and -9 mRNA increased 5- (P=0

28 ed a peptide with micromolar K(i) values for matrix metalloproteinase-1 and -9 that are selective inh

29 gle treatment, as shown by lower IL-6, IL-8, matrix metalloproteinase-1 and matrix metalloproteinase-

30 two biologically relevant polymorphic genes, matrix metalloproteinase-1 and myeloperoxidase.

31 emonstrated the presence of higher levels of matrix metalloproteinase-1 and SAF-1 in the inflamed joi

32 Downregulated transcripts included matrix metalloproteinase-1 and thrombomodulin.

33 xpression of extracellular matrix-remodeling matrix metalloproteinases 1 and 10 (MMP1 and MMP10), sug

34 kin 1 to reduce production of collagenolytic matrix metalloproteinases 1 and 13 in tenosynovial tissu

35 ation of antimetastatic tissue inhibitors of matrix metalloproteinases 1 and 2 and plasminogen activa

36 epiregulin, the cyclooxygenase COX2, and the matrix metalloproteinases 1 and 2, when expressed in hum

37 ion, relaxin decreases endometrial levels of matrix metalloproteinases 1 and 3 and increases levels o

38 cellular matrix remodeling, and they include matrix metalloproteinases 1 and 3, IL-8, human beta-defe

39 f a number of chondrocyte proteins including matrix metalloproteinases 1 and 3, tissue inhibitor of m

40 g in adhesive signaling and up-regulation of matrix metalloproteinases 1 and 3.

41 ange in C-reactive protein (CRP) degraded by matrix metalloproteinases 1 and 8 (CRPM) from baseline t

42 n of inducible nitric oxide synthase (iNOS), matrix metalloproteinases 1 and 8 (MMP-1 and -8), bone m

43 ects were also associated with a decrease of matrix metalloproteinases 1 and 8, inducible nitric oxid

44 ors alpha and beta, and tissue inhibitors of matrix metalloproteinases-1 and -2, increased by 4 weeks

45 Membrane-type matrix metalloproteinases-1 and -3 (MT1- and MT3-MMPs) a

46 giogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3.

47 Matrix metalloproteinases-1 and -9 and tissue inhibitor

48 JAG2 also induced matrix-metalloproteinases 1 and 12, which are highly exp

49 inases 7, 9, 10, and 12, tissue inhibitor of matrix metalloproteinase 1, and secreted protein acidic

50 mural and luminal flow induced expression of matrix metalloproteinase 1, and this up-regulation was r

51 vated levels of the matrix degrading protein matrix metalloproteinase-1, and a promigratory phenotype

52 protein A8, IL-6, IL-8, and tissue inhibitor matrix metalloproteinase-1 are up-regulated by these NOS

53 nd its inhibitor TIMP-1 (tissue inhibitor of matrix metalloproteinase 1) are regulated in a manner th

54 cells depend on up-regulation of Drosophila matrix metalloproteinase-1 as assessed by promoter activ

55 Mechanistically, BCBM cell-secreted matrix metalloproteinase 1 binds to protease-activated r

56 tril/valsartan decreased tissue inhibitor of matrix metalloproteinase 1 by 8% (95% confidence interva

57 21SNFT in HepG2 cells leads to repression of matrix metalloproteinase-1 by 70-80%.

58 indicate that the mechanism of repression of matrix metalloproteinase-1 by p21SNFT may be exploited i

59 es that may be involved in the repression of matrix metalloproteinase-1 by p21SNFT.

60 decreases the expression of the collagenase, matrix metalloproteinase 1, by IL-34-Mphi and M-CSF-Mphi

61 e of collagen I and III, tissue inhibitor of matrix metalloproteinase 1, carboxyl-terminal telopeptid

62 In mice, transgenic expression of human matrix metalloproteinase 1 causes caseous necrosis, the

63 al telopeptide of collagen type I (CITP) and matrix metalloproteinase-1 (CITP:MMP-1) was determined i

64 e designed to include cell-adhesion ligands, matrix metalloproteinase-1 cleavage sites, and full-leng

65 inase-9 (gelatinase B; pro-MMP-9) and active matrix metalloproteinase-1 (collagenase-1; MMP-1).

66 e plasminogen activator, tissue inhibitor of matrix metalloproteinase-1, cyclooxygenase-2, and VEGF r

67 or collagens, laminins, decorin, E-cadherin, matrix metalloproteinase-1, endorepellin, and several vi

68 ed with increased neutrophil recruitment and matrix metalloproteinase-1 expression, both involved in

69 GBP1 was required for EGFR-mediated MMP1 (matrix metalloproteinase 1) expression and glioma cell i

70 SLFN5 negatively controls expression of the matrix metalloproteinase 1 gene (MMP-1), MMP-13, and sev

71 dose UV-A1 irradiation significantly induced matrix metalloproteinase 1 gene expression, which increa

72 metalloproteinase 2 and tissue inhibitor of matrix metalloproteinase 1 gene expression.

73 mulatory effect of insulin on collagenase-1 (matrix metalloproteinase-1) gene transcription a series

74 cular endothelial growth factor, KDR, Ang-2, matrix metalloproteinase 1, GRO-alpha, and CD31).

75 growth factor receptor, estrogen signaling, matrix metalloproteinase-1, histone deacetylase, methylt

76 degeneration through the regulation of human matrix metalloproteinase-1 (hMMP-1, collagenase-1) gene

77 , IL-20, chemokine C-X-C motif ligand 8, and matrix metalloproteinase 1, IL-19 had no clear influence

78 ype 1 collagen genes and tissue inhibitor of matrix metalloproteinase 1 in both wild-type and egr-1(-

79 RANTES stimulated the release of matrix metalloproteinase 1 in normal and OA chondrocytes

80 The expression of collagenase (matrix metalloproteinase 1) in human fibroblasts increas

81 coprotein transporter protein gene and MMP1 (Matrix Metalloproteinase 1), indicative of the invasive

82 a occludens-1, laminin), tissue inhibitor of matrix metalloproteinase-1, inflammation (interleukin-1b

83 of type I collagen were exposed in vitro to matrix metalloproteinase-1 (interstitial collagenase), a

84 Increased synthesis of SAA and matrix metalloproteinase-1 is associated with pathogenes

85 rix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase 1, left atrial volume), myocard

86 le to regression mediated by factors such as matrix metalloproteinase-1, matrix metalloproteinase-10,

87 eutralizing reagents blocked hypoxia-induced matrix metalloproteinase-1, matrix metalloproteinase-9 e

88 in humans suggest that PTX3, P-selectin, and matrix metalloproteinase-1 may be novel biomarkers that

89 fibroblasts in response to stimulation were matrix metalloproteinase 1, MCP-1, IL-1beta, IL-6, IL-8,

90 The 1G/2G polymorphism of matrix metalloproteinase 1 (MMP-1) affects activity of t

91 Presently, matrix metalloproteinase 1 (MMP-1) and collagen triple-h

92 a1 (TGFbeta1) resulted in down-regulation of matrix metalloproteinase 1 (MMP-1) and MMP-13 concomitan

93 or retinoid X receptor, on the expression of matrix metalloproteinase 1 (MMP-1) and MMP-13 induced by

94 Elevations in matrix metalloproteinase 1 (MMP-1) and MMP-3 have been f

95 infection and elevated expression of tissue matrix metalloproteinase 1 (MMP-1) are both associated w

96 Matrix metalloproteinase 1 (MMP-1) cleaves types I, II,

97 Matrix metalloproteinase 1 (MMP-1) expression in cell cu

98 Catalysis of collagen degradation by matrix metalloproteinase 1 (MMP-1) has been proposed to

99 in inhibitor, Dec-RVKR-CH(2)Cl, or selective matrix metalloproteinase 1 (MMP-1) inhibitors.

100 Matrix metalloproteinase 1 (MMP-1) plays a pivotal role

101 inase Calpha (PKCalpha) and the induction of matrix metalloproteinase 1 (MMP-1) through extracellular

102 east in part, by interstitial collagenase 1 (matrix metalloproteinase 1 (MMP-1)).

103 duction of mRNA for CXCL8/IL-8, CCL5/RANTES, matrix metalloproteinase 1 (MMP-1), and MMP-3 after TNFa

104 aspase 8, Fas, Fas ligand, p53, aggrecanase, matrix metalloproteinase 1 (MMP-1), and MMP-3.

105 Levels of messenger RNA (mRNA) for matrix metalloproteinase 1 (MMP-1), MMP-13, and ADAMTS-4

106 or ligand superfamily member 13B (TNFSF13B), matrix metalloproteinase 1 (MMP-1), MMP-2, and MMP-3.

107 cytokine combination synergistically induced matrix metalloproteinase 1 (MMP-1), MMP-3, and MMP-13 mR

108 ative levels of mRNA for aggrecan, tenascin, matrix metalloproteinase 1 (MMP-1), MMP-3, and tissue in

109 Matrix metalloproteinase 1 (MMP-1), one of the Ets-1 dow

110 ermal fibroblasts revealed overexpression of matrix metalloproteinase 1 (MMP-1), the gene encoding th

111 agen and phospho-Smad3 and reduced levels of matrix metalloproteinase 1 (MMP-1).

112 ulcerations of any form is the expression of matrix metalloproteinase 1 (MMP-1; collagenase-1) by lea

113 association occurred only in carriers of the matrix metalloproteinase-1 (MMP-1) 2G (rs1799750) or the

114 ric collagen I by both the human collagenase matrix metalloproteinase-1 (MMP-1) and collagenase from

115 ased the expression of MMP1, which codes for matrix metalloproteinase-1 (MMP-1) and is responsible fo

116 RATIONALE: Matrix metalloproteinase-1 (MMP-1) and mast cells are pr

117 d NF-kappaB can transactivate genes encoding matrix metalloproteinase-1 (MMP-1) and MMP-9.

118 rin by type I collagen induces expression of matrix metalloproteinase-1 (MMP-1) and that MMP-1 activi

119 of endoglin in modulating Ang II effects on matrix metalloproteinase-1 (MMP-1) and type I collagen e

120 We used matrix metalloproteinase-1 (MMP-1) as a model protease a

121 Importantly, we identify matrix metalloproteinase-1 (MMP-1) as a novel downstream

122 ainst interleukin-8 (IL-8) and inhibition of matrix metalloproteinase-1 (MMP-1) expression before and

123 Increased matrix metalloproteinase-1 (MMP-1) expression is associa

124 terleukin-8 (IL-8) and for the inhibition of matrix metalloproteinase-1 (MMP-1) expression, an inflam

125 uent downstream transcriptional increases in matrix metalloproteinase-1 (MMP-1) expression, which wer

126 e that Met controls the transcription of the matrix metalloproteinase-1 (MMP-1) gene in carcinoma cel

127 reeclampsia involves increased expression of matrix metalloproteinase-1 (MMP-1) in endothelial cells,

128 Iris and CB were the major source of matrix metalloproteinase-1 (MMP-1) in the naive eye, and

129 We find astrocytic matrix metalloproteinase-1 (MMP-1) induced by critical p

130 Matrix metalloproteinase-1 (MMP-1) is a collagenase that

131 Our previous studies demonstrated that matrix metalloproteinase-1 (MMP-1) is able to digest fib

132 Matrix metalloproteinase-1 (MMP-1) is highly expressed b

133 cted to determine the following: (1) whether matrix metalloproteinase-1 (MMP-1) is increased in syste

134 Extracellular matrix-degrading matrix metalloproteinase-1 (MMP-1) is one of the interst

135 A polymorphism at -1607 in the matrix metalloproteinase-1 (MMP-1) promoter (an insertio

136 amined the hypothesis that H. pylori induces matrix metalloproteinase-1 (MMP-1) secretion, with poten

137 hat smoke exposure leads to the induction of matrix metalloproteinase-1 (MMP-1) through the activatio

138 tokine release and the induction of mRNA for matrix metalloproteinase-1 (MMP-1) were also studied usi

139 In injured skin, collagenase-1 (matrix metalloproteinase-1 (MMP-1)) is induced in migrat

140 ll forms of cutaneous wounds, collagenase-1 (matrix metalloproteinase-1 (MMP-1)) is invariably expres

141 roblasts, and the production of collagenase (matrix metalloproteinase-1 (MMP-1)), the major enzyme in

142 The expression of cyclooxygenase-2 (COX-2), matrix metalloproteinase-1 (MMP-1), and the production o

143 howing that it transcriptionally upregulates matrix metalloproteinase-1 (MMP-1), and using rescue app

144 or collagens, laminins, decorin, E-cadherin, matrix metalloproteinase-1 (MMP-1), endorepellin, and se

145 One factor, matrix metalloproteinase-1 (MMP-1), is induced in Drosop

146 Matrix metalloproteinase-1 (MMP-1), or interstitial coll

147 A levels of six senescence-associated genes, matrix metalloproteinase-1 (MMP-1), was decreased, while

148 ype I procollagen and concurrently increases matrix metalloproteinase-1 (MMP-1), which initiates fibr

149 e production of the interstitial collagenase matrix metalloproteinase-1 (MMP-1), which is expressed s

150 ary tube regression in these cocultures in a matrix metalloproteinase-1 (MMP-1)-, MMP-10-, and ADAM-1

151 ed after 24 h of stretch with an increase in matrix metalloproteinase-1 (MMP-1).

152 Many tumor types express matrix metalloproteinase-1 (MMP-1); its collagenase acti

153 Enhanced production of matrix metalloproteinase-1 (MMP-1, collagenase-1) is imp

154 Matrix metalloproteinase-1 (MMP-1, collagenase-1), which

155 ns retinoic acid (atRA) on the expression of matrix metalloproteinase-1 (MMP-1, interstitial collagen

156 ture and human skin organ culture, levels of matrix metalloproteinase-1 (MMP-1; interstitial collagen

157 .000), IL-8/CXCL8 (P=0.006), IL-6 (P=0.002), matrix metalloproteinase-1 (MMP-1; P=0.002), and MMP-3 (

158 press increased levels of collagen-degrading matrix metalloproteinases-1 (MMP-1) in aged (>80 years o

159 Gene expression and protein production of matrix metalloproteinases-1 (MMP-1), -2, -3, -13, and -1

160 loid protein A [SAA]), inflammatory markers (matrix metalloproteinase 1 [MMP-1] and heme oxygenase 1

161 The levels of collagenase (matrix metalloproteinase 1 [MMP-1]) and tissue inhibitor

162 a induced significant levels of collagenase (matrix metalloproteinase 1 [MMP-1]) within 4 hours, and

163 Levels of fibroblast collagenase (matrix metalloproteinase 1 [MMP-1]), neutrophil collagen

164 Levels of matrix metalloproteinases (matrix metalloproteinase 1 [MMP-1], MMP-13, and MMP-3),

165 e upregulated genes (lactotransferrin [LTF], matrix metalloproteinase-1 [MMP-1], MMP-3, interferon in

166 e accumulation and interstitial collagenase (matrix metalloproteinase-1, MMP-1) expression in the les

167 and degradation by interstitial collagenase (matrix metalloproteinase-1, MMP-1) may determine whether

168 of SphK1 in the regulation of expression of matrix metalloproteinase 1 (MMP1) in dermal fibroblasts,

169 sed by preincubating HCECs with capsazepine, matrix metalloproteinase 1 (MMP1) inhibitor TIMP-1, broa

170 Matrix metalloproteinase 1 (MMP1) is required in trachea

171 hermore, inhibition of Akt upregulated basal matrix metalloproteinase 1 (MMP1) production and reverse

172 upregulation of the interstitial collagenase/matrix metalloproteinase 1 (MMP1) promoter.

173 essential for controlling the expression of matrix metalloproteinase 1 (Mmp1), a major regulator of

174 R-cad also suppressed the matrix metalloproteinase 1 (MMP1), MMP2, and cyclooxygen

175 ess that may be mediated by the DKK effector matrix metalloproteinase 1 (MMP1).

176 r matrix (ECM) organization-related enzymes (matrix metalloproteinase-1 (MMP1) and metalloproteinase

177 nase (JNK)/AP-1 signaling, and expression of matrix metalloproteinase-1 (Mmp1) are activated downstre

178 ), augmenter of liver regeneration (alr) and Matrix metalloproteinase-1 (Mmp1) expressed specifically

179 Matrix metalloproteinase-1 (MMP1) initiates the cleavage

180 The ability of AHR to control expression of matrix metalloproteinase-1 (MMP1) was analyzed.

181 actor-alpha (TNF), interleukin-1beta (IL1B), matrix metalloproteinase-1 (MMP1), MMP-2, MMP-9, tissue

182 ase with thrombospondin motifs (ADAMTS1) and matrix metalloproteinase-1 (MMP1), orchestrate a paracri

183 ry dermal fibroblast cultures confirmed that matrix metalloproteinase 1 mRNA, MMP1, increased with ag

184 ry dermal fibroblast cultures confirmed that matrix metalloproteinase 1 mRNA, MMP1, increased with ag

185 lpha caused a rapid synergistic induction of matrix metalloproteinase 1 mRNA, which was sustained ove

186 Membrane type matrix metalloproteinase 1 (MT-MMP1), a novel 63-kDa mem

187 Membrane-type matrix metalloproteinase-1 (MT-MMP-1) has been proposed

188 Membrane-type matrix metalloproteinase 1 (MT1-MMP) is a key enzyme in

189 tion by binding to activated membrane type 1-matrix metalloproteinase 1 (MT1-MMP) on the plasma membr

190 Membrane-type matrix metalloproteinase 1 (MT1-MMP) plays a critical ro

191 Membrane-type matrix metalloproteinase-1 (MT1-MMP) plays a key role in

192 ion darkened skin slightly and did not alter matrix metalloproteinase 1 or type I procollagen gene ex

193 expression of the interstitial collagenase (matrix metalloproteinase-1 or MMP-1) gene.

194 The expression of matrix metalloproteinase-1, or procollagenase, was stimu

195 blunted nitric oxide production through the matrix metalloproteinase-1 pathway.

196 n the endothelial layer through a P-selectin/matrix metalloproteinase-1 pathway.

197 ession and suppress transcription of a human matrix metalloproteinase 1 promoter reporter construct i

198 p21SNFT interacted with Jun at the matrix metalloproteinase-1 promoter -88 Ets/AP-1 enhance

199 Notably, matrix metalloproteinase-1 promoter region, tissue inhib

200 eceptor mRNA expression also correlated with matrix metalloproteinase-1 promoter region, tissue inhib

201 y activating both an E74 site-driven and the matrix metalloproteinase-1 promoter.

202 y-terminal telopeptide of collagen type-I to matrix metalloproteinase-1 ratio) and with excessive myo

203 ry products (ie, matrix metalloproteinase 12/matrix metalloproteinase 1/S100A9) were upregulated in b

204 collagen deposition and tissue inhibitor of matrix metalloproteinase-1 secretion induced by hepatic

205 d the exclusive presence of proinflammatory (matrix metalloproteinase 1(+)) stromal cells.

206 els of PTX3 and its mediators P-selectin and matrix metalloproteinase-1 than normotensive subjects (n

207 f type III collagen, and tissue inhibitor of matrix metalloproteinase 1 that was subsequently evaluat

208 F-kappaB, promote induction of membrane-type matrix metalloproteinase-1 that then activates pro-MMP-2

209 ammation-responsive genes, including SAA and matrix metalloproteinase-1, that are implicated in the p

210 tion, the maintenance of tissue inhibitor of matrix metalloproteinase-1, the consequent preservation

211 d selective induction of tissue inhibitor of matrix metalloproteinase-1; this extracellular matrix re

212 -1 (MMP1), MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), TIMP-2, and hypoxan

213 or are increased whereas tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) expression in the ir

214 To examine whether tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) is changed to regula

215 SNX, and the effects of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) neutralization on th

216 or-alpha (TNF-alpha) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) while up-regulating

217 Serum tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), amino-terminal pept

218 hage markers arginase-1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and macrophage gala

219 mRNAs as well as that of tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) compared to subleth

220 Levels of MMP-1 (matrix metalloproteinase-1), TIMP-1 (tissue inhibitor of

221 nic role of the cytokine tissue inhibitor of matrix metalloproteinases 1 (TIMP1) in primary pancreati

222 (Col1a2) promoter, but in contrast to reduce matrix metalloproteinase 1 transcript expression and sup

223 ndothelial growth factor, interleukin-1beta, matrix metalloproteinase-1, versican, and fibronectin.

224 cid synthase 2 was highly expressed, whereas matrix metalloproteinase 1 was elevated in the dermal pa

225 down-regulated, and genes encoding IL-10 and matrix metalloproteinase 1 were up-regulated.

226 proteinases-1 and -9 and tissue inhibitor of matrix metalloproteinase-1 were strongly upregulated by

227 irradiation also induced tissue inhibitor of matrix metalloproteinases-1, which regulates the enzyme.

228 uding serum amyloid A, gamma-fibrinogen, and matrix metalloproteinase 1, whose abnormal expression is

229 increased expression of tissue inhibitor of matrix metalloproteinase-1 with decreased activity of ma